Goldman Sachs Adjusts Price Target on Pentair to $85 From $91, Maintains Neutral Rating
Pentair (PNR) has an average rating of outperform and price targets ranging from $78 to $101, according to analysts polled by Capital IQ.
Pentair Plc's (NYSE:PNR) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
It is hard to get excited after looking at Pentair's (NYSE:PNR) recent performance, when its stock has declined 7.9% over the past three months. But if you pay close attention, you might gather that
Deutsche Bank Adjusts Price Target on Pentair to $90 From $89, Maintains Buy Rating
Pentair (PNR) has an average rating of outperform and price targets ranging from $78 to $101, according to analysts polled by Capital IQ.
Baird Maintains Pentair(PNR.US) With Hold Rating, Cuts Target Price to $85
Baird analyst Michael Halloran maintains $Pentair(PNR.US)$ with a hold rating, and adjusts the target price from $86 to $85.According to TipRanks data, the analyst has a success rate of 59.7% and a to
Seaport Global Maintains Pentair(PNR.US) With Buy Rating, Cuts Target Price to $98
Seaport Global analyst Scott Graham maintains $Pentair(PNR.US)$ with a buy rating, and adjusts the target price from $100 to $98.According to TipRanks data, the analyst has a success rate of 59.9% and
Express News | Pentair PLC : Barclays Cuts Target Price to $90 From $95
Barclays Adjusts Price Target on Pentair to $90 From $95
Pentair (PNR) has an average rating of outperform and price targets ranging from $78 to $101, according to analysts polled by Capital IQ. Price: 74.60, Change: +0.29, Percent Change: +0.39
US stocks dig gold | The two giants of weight-loss drugs have refreshed their heights! Novo Nordisk's weight-loss drug has been approved for sale in China; performance has ignited stock prices! Carnival Cruise Line soared nearly 9% after the results.
Medical global sectors are rebounding! Intuitive Surgical rose more than 3%, up more than 30% this year, with an average annual ROI of 24% over the past 15 years. Alnylam Pharmaceuticals rose nearly 8%, up more than 55% in the past four trading days, and positive phase 3 data for new drugs is still fermenting. Regeneron Pharmaceuticals rose nearly 1%, up more than 20% this year, with RBC Capital Markets analyst maintaining a target price of $1229 per share.
Barclays Maintains Pentair(PNR.US) With Buy Rating, Cuts Target Price to $90
Barclays analyst Julian Mitchell maintains $Pentair(PNR.US)$ with a buy rating, and adjusts the target price from $95 to $90.According to TipRanks data, the analyst has a success rate of 66.8% and a t
Pool Corporation Stock Falls on Weak Summer Demand for Pools
RBC Capital Maintains Pentair(PNR.US) With Buy Rating, Cuts Target Price to $99
RBC Capital analyst Deane Dray maintains $Pentair(PNR.US)$ with a buy rating, and adjusts the target price from $103 to $99.According to TipRanks data, the analyst has a success rate of 62.9% and a to
Shares of Building-related Stocks Are Trading Lower After Pool Corp. Lowered Its FY24 EPS Forecast and Issued a Warning That Discretionary Pool Spending to Be Hampered by the Macroeconomic Environment.
Shares of Building-related Stocks Are Trading Lower After Pool Corp. Lowered Its FY24 EPS Forecast and Issued a Warning That Discretionary Pool Spending to Be Hampered by the Macroeconomic Environment
Pentair on Pace for Largest Percent Decrease Since June 2020 -- Data Talk
Pentair plc (PNR) is currently at $75.60, down $4.41 or 5.51% --Would be lowest close since Feb. 22, 2024, when it closed at $75.29 --On pace for largest percent decrease since June 11, 2020, when i
Expert Ratings For Pentair
During the last three months, 9 analysts shared their evaluations of Pentair (NYSE:PNR), revealing diverse outlooks from bullish to bearish.The following table summarizes their recent ratings, sheddin
Stifel Maintains Pentair(PNR.US) With Buy Rating, Maintains Target Price $94
Stifel analyst Nathan Jones maintains $Pentair(PNR.US)$ with a buy rating, and maintains the target price at $94.According to TipRanks data, the analyst has a success rate of 65.7% and a total average
Pentair Price Target Cut to $99.00/Share From $103.00 by RBC Capital
Pentair Price Target Cut to $99.00/Share From $103.00 by RBC Capital
Pentair Is Maintained at Outperform by RBC Capital
Pentair Is Maintained at Outperform by RBC Capital
RBC Capital Maintains Outperform on Pentair, Lowers Price Target to $99
RBC Capital analyst Deane Dray maintains Pentair with a Outperform and lowers the price target from $103 to $99.
Pentair Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/25/2024 27.74% RBC Capital $103 → $99 Maintains Outperform 04/24/2024 9.68% TD Cowen $80 → $85 Maintain
Baird Adjusts Price Target on Pentair to $85 From $86
Pentair (PNR) has an average rating of outperform and price targets ranging from $78 to $101, according to analysts polled by Capital IQ. Price: 77.40, Change: -2.60, Percent Change: -3.25